Adjuvant Radiotherapy Linked With Survival Benefit After Distal Cholangiocarcinoma Resection


Data published in Cancer found adjuvant radiotherapy after distal cholangiocarcinoma resection was associated with a survival benefit for patients, regardless of margin or nodal status.

Patients who underwent adjuvant radiotherapy (RT) after resection of distal cholangiocarcinoma (dCCA) experienced a survival benefit, even in those with margin-negative or node-negative resections, according to data published in Cancer.

Because of this survival benefit association, the investigators suggest that adjuvant RT be considered routinely after resection of dCCA, regardless of margin and nodal status.

“In this large national registry analysis including 8233 patients, adjuvant RT after resected dCCA was associated with improved survival after multivariable adjustment and accounting for treatment-selection bias,” wrote the investigators. “Subset analyses revealed that this benefit was maintained irrespective of pathological nodal and margin status.”

After propensity score matching was used to account for treatment-selection bias, adjuvant therapy was associated with improved survival, with medians of 29.3 versus 26.8 months (P <.001).

The survival benefit association remained after multivariable adjustment (HR, 0.86; 95% CI, 0.80-0.93; P <.001). Moreover, a multivariable interaction analysis revealed that the benefit existed irrespective of nodal status (N0: HR, 0.77; 95% CI, 0.66-0.89; P <.001; N+: HR, 0.79; 95% CI, 0.71-0.89; P <.001) or margin status (R0: HR, 0.58; 95% CI, 0.50-0.67; P <.001; R1: HR, 0.87; 95% CI, 0.78-0.96; P = .007).

After propensity score matching was completed, 1509 patients (34%) receiving adjuvant RT and 1509 (66%) with no RT remained of the initial groups (2162 and 4155, respectively). Specifically, the rate of node-negative disease was 39%, node-positive disease was 51%, and unknown node status was 10%.

“In this large nationwide retrospective study, adjuvant RT was associated with a survival benefit in patients with resected dCCA, regardless of pathological nodal involvement, resection margin status, and receipt of adjuvant CT,” wrote the investigators. “These data suggest adjuvant RT should be broadly considered in the multimodality treatment of dCCA.”

The team of investigators identified patients undergoing pancreatoduodenectomy for nonmetastatic dCCA via the National Cancer Database from 2004 to 2016. Patients who underwent neoadjuvant RT and chemotherapy with survival of less than 6 months were excluded from the study’s population.

Even though the investigators utilized propensity score matching to eliminate treatment-selection bias, they acknowledge that a limitation of the research is the potential that residual bias remains. More, the duration of adjuvant chemotherapy and the specific regimens utilized are not readily available via the National Cancer Database. This limited the team’s ability to analyze the role of adjuvant RT-sensitizing chemotherapy with survival benefits.

“Broad acceptance of the routine use of adjuvant RT in dCCA would also support its use in the neoadjuvant setting, just as in pancreatic cancer, so that postoperative complications have less impact on the completion of multimodality therapy,” wrote the investigators.


Kamarajah SK, Bednar F, Cho CS, et al. Survival benefit with adjuvant radiotherapy after resection of distal cholangiocarcinoma: a propensity-matched national cancer database analysis. Cancer. December 15, 2020. doi: 10.1002/cncr.33356

Related Videos
Hypofractionated radiotherapy yields less financial toxicity than conventionally fractionated radiotherapy in patients with breast cancer who have undergone reconstruction following mastectomy.
Those with breast cancer who have undergone implant-based reconstruction following mastectomy have similar outcomes with hypofractionated vs conventionally fractionated radiotherapy.
Rates of obesity appear to correlate with increasing incidence of cancer in young populations, according to Monique Gary, DO, MSc, FACS.
An expert from Dana-Farber Cancer Institute indicates that urologists should refer patients with prostate cancer who present with multiple high-risk factors at surgery to a radiation and medical oncologist.
Fifteen-year results of the ProtecT prostate cancer trial may support the findings of the study’s 10-year follow-up data, according to an expert from Dana-Farber Cancer Institute.
Increasing age, higher Gleason scores, and higher pathologic stages are predictors of mortality in patients with prostate cancer, according to an expert from Dana-Farber Cancer Institute.
Clinical trials highlight benefits, including radiographic progression-free survival following treatment with radioligand 177Lu-PSMA-617 in pretreated patients with metastatic castration-resistant prostate cancer.
Early data from ongoing clinical trials suggest the potential safety and efficacy of novel radium-223 combinations as treatment for metastatic castration-resistant prostate cancer.
Current clinical trials look to assess 177Lu-PSMA-617 in combination with other therapies including androgen deprivation therapy and docetaxel.
An expert from Dana-Farber Cancer Institute indicates that patients with prostate cancer who have 1 risk factor should undergo salvage radiotherapy following radical prostatectomy before their prostate-specific antigen level rises above 0.25 ng/ml.
Related Content